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studies worldwide. METHODS: We searched Medline, EMBASE, and three other 
Chinese databases from their inception to June 2008. We included case-control and
cohort studies that investigated the association of smoking with lung cancer, and that
provided data on the magnitude of the association. Two reviewers screened the eligibil-
ity, assessed the extent of bias, and extracted data independently. We obtained unad-
justed and adjusted estimates of studies. We pooled the trial data using random-effect 
model and explored the heterogeneity by the pre-speciﬁ ed variables. RESULTS: We 
included 45 (n  71,869), 4 of which were cohort studies (n  48,250) and 41 case-
control studies (cumulative cases: 10,268, and controls: 13,351). Smoking increased 
the risk of lung cancer by 137% (OR 2.37, 95%CI 1.95 to 2.88). Pooling of adjusted 
estimates of in 32 studies showed that the risk of lung cancer was increased by 181% 
(2.81, 2.31 to 3.42). No gender difference was found in the association (15 studies): 
ORs were 3.19 (2.51 to 4.06) in male and 2.98 (2.29 to 3.89) in female (interaction
p  0.1). The risks were statistically different in different type of lung cancer: aden-
carcinoma 1.81 (1.23 to 2.66), squamous cell carcinoma 7.07 (2.34 to 21.38), and
small cell lung cancer 7.98 (4.22 to 15.11). The increased amount of smoking 
increased the risk of lung cancer (coef. 0.27, 0.03 to 0.51). No signiﬁ cant dose-
response was found between the risk of lung cancer and the duration and initiating 
age of smoking. CONCLUSIONS: The association between smoking and lung cancer
has been ascertained in the Chinese population. Pronounced heterogeneity in risks of 
lung cancer was found in different type of lung cancer and amount of smoking.
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OBJECTIVES: Increasing attention has been paid to team-based approaches to the 
management of patients with advanced prostate cancer (PCa). It is not known whether 
the timing of specialist contacts relative to treatment initiation is associated with sur-
vival. This study examines whether patients with visits to a medical oncologist/hema-
tologist (MOH) before treatment have better survival outcomes than those who see a
MOH after treatment begins. METHODS: A retrospective analysis of linked Surveil-
lance, Epidemiology, and Endpoints (SEER) – Medicare data included patients diag-
nosed with Stage IV PCa between 1994 and 2002 (age  65 years) who received 
treatment and a referral. Treatment was deﬁ ned as the receipt of orchiectomy, hormone 
therapy, chemotherapy, or radiation at any time following diagnosis. A referral was 
deﬁ ned as a post-diagnosis visit to an urologist followed by a visit to a MOH. The 
key covariate identiﬁ ed patients referred prior to treatment initiation. Colon cancer – 
speciﬁ c mortality models controlled for potential confounders including demographic, 
clinical, continuity-of-care, and ecological measures. RESULTS: A total of 2075
patients with Stage IV PCa met the inclusion criteria. The average age in the sample 
was 75 years and 83% were White. Seven percent of patients visited both specialists 
before receiving treatment. Referral visits prior to the start of treatment were associ-
ated with a reduction in the relative risk of disease – speciﬁ c mortality (HR: 0.7; 0.5 
– 0.9, p  0.02) in the full sample and in a propensity-matched sample (HR: 0.6; 0.4 
– 0.9, p  0.006). CONCLUSIONS: As treatment options for advanced stage PCa
evolve, patients may beneﬁ t from contact with a team of specialists. We ﬁ nd that there 
is a survival beneﬁ t associated with referrals that occur prior to treatment initiation. 
The results suggest that the timing of specialist visits is important for PCa survival. 
Further studies on referral patterns are needed to validate these results.
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OBJECTIVES: Atypical antipsychotics are currently the most frequently prescribed
class of drugs for schizophrenia. These drugs appear to be associated with varying
degrees of metabolic adverse effects. We conducted a retrospective clinical study to
evaluate the adverse metabolic effects of antipsychotic medications in schizophrenic 
patients in Taiwan population. METHODS: This is a retrospective observational 
study. A total of 431 outpatients who were diagnosed with schizophrenia and taken
clozapine or olanzapine or risperidone or haloperidol for more than one year were
included in this study. We excluded those who took other drugs known to affect 
glucose metabolism (including á, â-blockers, thiazide diuretics, phenytoin, valproate,
and corticosteroids), and those who were diagnosed with diabetes mellitus and hyper-
lipidemia at the initial time of study. The changes of blood lipids and fasting blood 
glucose levels noted in the medical records were reviewed and analyzed. RESULTS:
The results indicated that 298 outpatients showed weight gain after 6^8 months of 
medications. 83.3%(60/72) of risperidone-treated patients had experienced signiﬁ cant 
weight gain as compared with 48.8%(40/82) of clozapine and 4% (2/50) haloperidol 
treated patients (p  0.001). The potential risk of increased fasting blood glucose, 
cholesterol, and triglyceride levels for risperidone-treated patients were 50.5 o 4.2%, 
13.9 o 5.6% and 53.8 o 4.2%, respectively. 48 patients need additional drugs to regu-
late the increased metabolic levels, such as atorvastatin for increased triglyceride levels
and glucophage for increased blood glucose level. The extra medications expenditure 
used to regulate the adverse effect was about NT 13 million each year. CONCLU-
SIONS: The atypical antipsychotic drugs can cause adverse metabolic effects. Ameri-
can Diabetes Association (ADA) suggested to monitor patients’ body weight, fasting 
blood glucose, and lipid proﬁ le for those who are prescribed atypical antipsychotics.
Additionally, the diet control and regular exercise should be suggested to patients who
have already been getting weight in the treatment of atypical antipsychotics.
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OBJECTIVES: The aim of this study was to compare the effectiveness and servival
rate of cetuxiamb plus chemotherapy with the traditional chemotherapy alone in the 
treatment of metastatic colorectal cancer.( mCRC). METHODS: This is a retrospective 
observational study which was conducted from January 2004 to December 2008. 
Hospitalized patients diagnosed with mCRC and treated with chemotherapy regimen
of FOLFIRI (irinotecan/ 5-ﬂ uorouracil/ leucovorin) plus cetuximab or patients treated 
with FOLFIRI or FOLFOX (oxaliplatin/5-ﬂ uorouracil/leucovorin) chemotherapy 
regimen alone for a course of 1 year were recruited. The medical records for all 
patients recruited were evaluated by clinical pharmacist. T-test was used for analysis. 
RESULTS: A total of 143 patients were identiﬁ ed. Sixty-ﬁ ve patients were treated with 
FOLFIRI (irinotecan/ 5-ﬂ uorouracil/ leucovorin) plus cetuximab and seventy-eight 
patients were treated with FOLFIRI or FOLFOX alone. The results showed that total 
50 patients treated with FOLFIRI combined with cetuximab were survived about 17.3 
months, survival rate was 64%; whereas, total of 65 patients treated with FOLFIRI
or FOLFOX alone were survived about 12.9 months, survival rate was 41%. By using 
chemotherapy combined with cetuximab, the survival rate increased about 4.4 
momths as compared to the chemogtherapy alone. The difference of survival rate 
between two groups is statistical signiﬁ cant. (p value is 0.018). CONCLUSIONS: The 
preliminary result indicated that chemotherapy plus cetuximab is more effective as
compared to chemotherapy alone for mCRC patients. However, cetuximab is more
expensive target chemotherapeutic drugs in our country, therefore, evaluation on 
direct medical costs of two regimens is indispensable and data will be completed in 
the near future.
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OBJECTIVES: Recommended treatment duration of atrophic vaginitis in postmeno-
pausal women with vaginal estrogen (VE) is currently limited to 6–12 months, the
length of clinical trials conducted to date, due to concerns of potential development
of endometrial carcinoma. In practice, many women use VE longer. This study exam-
ines the association between VE use and risk of endometrial carcinoma over a 3 year 
follow-up period among Medicaid enrollees. METHODS: A retrospective cohort 
study was conducted using North Carolina Medicaid prescription and medical claims 
between January 1998 and December 2007. The study included women ages 18–64 
years with a prescription claim for VE (cream, tablet, and ring forms) or a diagnosis 
of atrophic vaginitis (identiﬁ ed by ICD-9 code 627.3). Demographic factors included
age and race (African American, white, or other). Comorbidity risk adjustment was
determined using the Charlson-Deyo method. Multiple logistic regression was per-
formed to assess the association of VE use and endometrial carcinoma adjusting for 
age, race, and comorbidities. RESULTS: A total of 770 patients prescribed VE (mean
age 50.1 years /8.4) and 881 patients diagnosed with atrophic vaginitis but not 
treated with VE (mean age 49.4 years /9.8) were identiﬁ ed in the database. Ten 
cases of uterine carcinoma were identiﬁ ed among the VE patients; 11 cases among 
women not prescribed VE. Logistic regression results showed no signiﬁ cant difference
in the occurrence of endometrial carcinoma between women on VE therapy and those 
not on VE therapy (OR  1.11, 95%CI: 0.47–2.65, P  0.814). Older age was the 
only signiﬁ cant predictor of uterine carcinoma (OR  1.11, 95%CI: 1.03–1.20, P 
0.008); i.e., for a ten-year increase in age, odds of endometrial carcinoma increased 
by a factor of 2.8. CONCLUSIONS: With three years of follow-up showed no associa-
tion between VE exposure and endometrial carcinoma. Increasing age was found to 
be the only signiﬁ cant risk factor.
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OBJECTIVES: The phase III trial AVOREN demonstrated that BEV  interferon-
alpha2a (IFN) prolongs progression-free survival compared with IFN  placebo in 
patients with untreated mRCC [Escudier, Lancet 2007]. The protocol speciﬁ ed that 
the recommended dose of IFN (9MIU 3x/week) could be lowered to 6 or 3MIU for 
grade q3 adverse events (AEs) attributable to IFN or other investigator-deﬁ ned 
reasons. A retrospective analysis of AVOREN showed that lower-dose (LD) IFN in 
combination with BEV improves tolerability and maintains clinical beneﬁ t [Melichar, 
Ann Oncol 2008]. We report here the costs of managing side effects of BEV  LD IFN 
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compared with BEV  IFN and sunitinib. METHODS: A linear decision analytic
model was developed to assess the management costs of all-grade and grade 3/4 AEs
for BEV  LD IFN from the perspective of health care purchasers in Germany, France
and UK. Data sources included published cost literature and clinical trials, ofﬁ cial
price/tariff lists and country-speciﬁ c cost databases. RESULTS: The total side-effect 
management costs for BEV  LD IFN were €908, €1,381 and €703 in Germany, France
and UK, respectively. The use of BEV  LD IFN provides reduced management costs 
per patient of €616, €576 and €606, respectively, compared with BEV  IFN, and
€1,286, €3,746 and €1,647, respectively, compared with sunitinib. The main drivers 
for sunitinib costs were thrombocytopenia, neutropenia and lymphopenia compared 
with fatigue/asthenia, proteinuria and anaemia for BEV  LD IFN. CONCLUSIONS:
Costs of managing the side effects of sunitinib treatment are greater than those for 
BEV  IFN in Germany, France and UK [Mickisch, ASCO 2008]. The present analysis 
shows that combining BEV with LD IFN is associated with the lowest side effect 
management costs. The tolerability proﬁ les and associated management costs of agents
used in mRCC may therefore inﬂ uence selection of therapy.
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OBJECTIVES: The combination of BEV  interferon-alpha2a (IFN) prolongs progres-
sion-free survival compared with IFN  placebo [Escudier, Lancet 2007], providing 
comparable efﬁ cacy to sunitinib in patients with mRCC. Notably, the type and fre-
quency of side effects differ between the two regimens. When selecting treatment 
options, the management of side effects and associated costs are important factors to 
consider for physicians and health care payers. A previous report showed that grade 
3/4 adverse events (AEs) account for the majority of side-effect management costs 
[Mickisch, ASCO 2008]. We report here the results of an updated analysis of grade 
3/4 AE management costs for BEV  IFN and sunitinib. METHODS: A linear decision
analytic model was developed to compare the management costs of grade 3/4 AEs of 
BEV  IFN and sunitinib from the perspective of health care purchasers or hospital-
based care in Germany, France, the UK and Italy. Data sources included published 
cost literature and clinical trials, ofﬁ cial price/tariff lists and country-speciﬁ c cost 
databases. RESULTS: The grade 3/4 AE management costs for sunitinib were higher
than those for BEV  IFN in Germany (€1785 vs €1367), France (€2590 vs. €1618), 
UK (€1475 vs. €804) and Italy (€891 vs. €402). The main cost drivers were country
dependent, but in general were lymphopenia, leucopenia, neutropenia, thrombocyto-
penia and fatigue/asthenia for sunitinib; the main cost drivers for BEV  IFN were
proteinuria, fatigue/asthenia, bleeding, anaemia and gastrointestinal perforation. The
difference in management costs between the two regimens was mainly due to the 
higher incidence of haematological side effects with sunitinib compared with BEV 
IFN and their associated high management costs. CONCLUSIONS: The costs of 
managing AEs of sunitinib are greater than those for BEV  IFN in Germany, France,
UK and Italy. AE proﬁ les are therefore an important consideration when selecting
treatments for mRCC.
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OBJECTIVES: To assess the incidence rate and risk factors of severe infusion reactions 
(IRs), and to quantify the costs associated with their management in patients with 
colorectal cancer (CRC) treated with cetuximab. METHODS: Using administrative 
claims of a US national commercially insured population, the study evaluates patients
with CRC receiving cetuximab treatment from 2004 to 2006. An algorithm was 
developed to identify IRs using a combination of three indicators: outpatient diagnoses 
of signs/symptoms of IRs, outpatient treatment for IRs, and ER visits or hospitaliza-
tions for IRs. IRs were categorized as severe based on the occurrence of an ER visit/
hospitalization with an IR admitting diagnosis; or presence of both outpatient diag-
nosis of IR signs/symptoms and outpatient IR treatment. Total costs associated with
each cetuximab administration were calculated. A logistic regression was run to iden-
tify risk factors for IRs. A Generalized Linear Model regression controlling for demo-
graphic and clinical characteristics was conducted to quantify additional economic
impact of severe IRs. RESULTS: A total of 1,122 patients were identiﬁ ed with 12,367 
cetuximab administrations. The incidence of severe IRs was 8.4%. Approximately
38% of patients experiencing severe IRs required an ER visit or hospitalization. Mean 
adjusted costs were $6,339 for administrations resulting in a severe IR that required 
outpatient treatment only; $13,174 for administrations resulting in a severe IR that
required an ER visit or hospitalization; and $4,450 for administrations without an 
IR. Younger age was associated with a statistically higher likelihood of IRs. Living in
states with high pollen counts also had a trend of increased likelihood of severe IRs,
although it was not statistically signiﬁ cant. CONCLUSIONS: The rate of severe IRs
with cetuximab in clinical practice was found to be higher than that reported in the
product labeling and clinical trials. Total costs associated with managing severe IRs 
to payers were substantial.
CANCER – Cost Studies
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OBJECTIVES: Myeloid growth factors are used to treat and prevent chemotherapy-
induced neutropenia (CIN). Filgrastim and its long-acting version pegﬁ lgrastim are
granulocyte colony-stimulating factors (G-CSF), whereas sargramostim is a dual 
granulocyte-macrophage colony-stimulating factor (GM-CSF). This study analyzed 
the budget impact of substituting GM-CSF for G-CSF in the management of CIN from 
the perspective of a US health plan. METHODS: A spreadsheet model was developed
to compute annual and per-member-per-month (PMPM) costs associated with CSFs.
Inputs included cancer prevalence, the proportion of patients receiving chemotherapy 
and G/GM-CSFs, incidence and treatment cost of relevant adverse events (e.g., bone 
pain), and G/GM-CSF drug acquisition and administration costs. Incidence and cost 
of infection- and febrile neutropenia-related hospitalizations, based on recent analysis 
of medical insurance claims data, were also used. Cost savings (2006 USD) were
assessed for utilization share switches from G-CSF to GM-CSF. RESULTS: For a health 
plan with 1 million members, an estimated 976 patients received G/GM-CSF annually.
Modifying baseline utilization shares for pegﬁ lgrastim, ﬁ lgrastim, and sargramostim
of 70/30/0%, respectively, to alternative shares of 50/25/25% yielded almost $2 
million in annual cost savings, or $0.161 PMPM. Most of the cost savings were 
attributed to CSF acquisition and administration costs (81.8%), with lesser savings 
also observed for hospitalizations (14.6%) and adverse events (3.6%). Savings for
patients switching from pegﬁ lgrastim were greater than for patients switching from
ﬁ lgrastim. Results were sensitive to assumptions for drug cost and frequency of 
administration, but cost savings were observed for most scenarios. CONCLUSIONS:
This study suggests that health plans can realize substantial cost savings by substituting 
sargramostim for ﬁ lgrastim and pegﬁ lgrastim in CIN patients. With 25% of sar-
gramostim substitution, cost savings could reach more than 16 cents PMPM for a
typical US health plan.
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OBJECTIVES: Pemetrexed plus cisplatin (Cis/Pem) was recently approved in the US
as initial treatment for advanced nonsquamous NSCLC. We developed a budget 
impact model to estimate the effect on a US health plan budget of adopting Cis/Pem
for this new indication. METHODS: A deterministic Excel-based budget impact model
was developed from the perspective of a one million member US health plan over a 
one-year time horizon. A survey of nine US thoracic oncologists was used to quantify
the impact of introducing Cis/Pem as ﬁ rst-line therapy on the frequency of chemo-
therapy use and the choice of ﬁ rst- and second-line regimens. Results were calculated 
from SEER incidence rates and the anticipated changes in ﬁ rst- and second-line 
regimen utilization rates. The costs associated with each regimen were based on 
Medicare reimbursement rates and a claims database analysis. Model outputs included
health plan total cost, cost per patient per year, and per member per month (PMPM) 
costs. RESULTS: Following the adoption of Cis/Pem, total cost per patient per year 
for advanced NSCLC is estimated to decrease by $702 from $67,539 to $66,837.
Anticipating that the number of NSCLC patients receiving treatment over the course
of one year would increase slightly, a net additional cost to the health plan of $35,512 
is estimated. Overall a neutral PMPM cost ($0.00) is expected. Most sensitivity analy-
ses produce PMPM costs between $0.02 and $0.02. CONCLUSIONS: Introduction 
of Cis/Pem as ﬁ rst-line therapy is anticipated to reduce the use of less expensive doublet 
regimens including gemcitabine and paclitaxel; however, it is also anticipated to reduce 
the use of more expensive triplet regimens containing bevacizumab. When Cis/Pem is 
used as ﬁ rst-line therapy, alternative, and often less expensive, regimens are recom-
mended for use as second-line therapy. Overall, the adoption of Cis/Pem as ﬁ rst-line 
therapy for advanced nonsquamous NSCLC is anticipated to be budget neutral.
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OBJECTIVES: to assess the ﬁ nancial consequences of the introduction of erlotinib as
second/third line treatment of patients with IIIB/IV NSCLC in Poland. METHODS:
Two scenarios were compared: “baseline scenario” where 96% patients received 
